MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2020)

According to our recent payer coverage analysis for type 2 Diabetes (GLP-1 and Combo) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for type 2 Diabetes (GLP-1 and Combo) treatments shows that under the pharmacy benefit, almost 37% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: With the cost of diabetes drugs still growing, PBMs and payers are looking for more innovative strategies to hold down costs. For some, that might include a strategy similar to the one unveiled by CVS Health Corp.’s Caremark unit in 2020. The plan, called RxZERO, offers a slimmer formulary for the diabetes drug class, but with no out-of-pocket costs for members.



AIS Health Staff

Related Posts
December 3

MMIT Reality Check on Ovarian Cancer

Read More
November 24

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo)

Read More
November 19

MMIT Reality Check on Colorectal Cancer

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today